Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Alexander W den Hartog"'
Autor:
Romy Franken, Stijntje Hibender, Alexander W den Hartog, Teodora Radonic, Carlie J M de Vries, Aeilko H Zwinderman, Maarten Groenink, Barbara J M Mulder, Vivian de Waard
Publikováno v:
PLoS ONE, Vol 9, Iss 9, p e107221 (2014)
AIMS:Patients with Marfan syndrome have an increased risk of life-threatening aortic complications, mostly preceded by aortic dilatation. In the FBN1(C1039G/+) Marfan mouse model, losartan decreases aortic root dilatation. We recently confirmed this
Externí odkaz:
https://doaj.org/article/291beb41452c49dbb62569b3b81539e6
Autor:
Alexander W. den Hartog, MD, Evelien Jansen, MD, Jasper E. Kal, MD, PhD, Debby Duyndam, MD, PhD, Jeldican Visser, MD, PhD, Pepijn van den Munckhof, MD, PhD, Jonas S.S.G. de Jong, MD, PhD, Krischan D. Sjauw, MD, PhD
Publikováno v:
HeartRhythm Case Reports, Vol 3, Iss 1, Pp 73-77 (2017)
Externí odkaz:
https://doaj.org/article/1de98cac2c78467d9fd36d119e46823d
Autor:
Niels MR van der Sangen, I Tarik Küçük, Jurriën M ten Berg, Marcel AM Beijk, Ronak Delewi, Alexander W den Hartog, Yolande Appelman, Niels JW Verouden, Wouter J Kikkert, José PS Henriques, Bimmer EPM Claessen
Publikováno v:
van der Sangen, N M R, Küçük, I T, ten Berg, J M, Beijk, M A M, Delewi, R, den Hartog, A W, Appelman, Y, Verouden, N J W, Kikkert, W J, Henriques, J P S & Claessen, B E PM 2022, ' P2Y12-inhibitor monotherapy after coronary stenting : are all P2Y12-inhibitors equal? ', Expert Review of Cardiovascular Therapy, vol. 20, no. 8, pp. 637-645 . https://doi.org/10.1080/14779072.2022.2104248
Introduction: P2Y(12)-inhibitor monotherapy following 1-3 months of dual antiplatelet therapy (DAPT) reduces (major) bleeding without an apparent increase in ischemic events and has therefore emerged as an alternative to 6-12 months of DAPT following
Autor:
Niels Mr, van der Sangen, I Tarik, Küçük, Jurriën M, Ten Berg, Marcel Am, Beijk, Ronak, Delewi, Alexander W, den Hartog, Yolande, Appelman, Niels Jw, Verouden, Wouter J, Kikkert, José Ps, Henriques, Bimmer Epm, Claessen
Publikováno v:
Expert review of cardiovascular therapy. 20(8)
P2YThis review critically appraises the evidence for P2YP2Y
Autor:
Maarten Groenink, Aeilko H. Zwinderman, Barbara J.M. Mulder, Romy Franken, Gerard Pals, Alexander W. den Hartog, Michael N. Singh
Publikováno v:
Progress in pediatric cardiology, 34(1), 9-14. Elsevier Ireland Ltd
Marfan syndrome is a multi-system connective tissue disorder, with primary involvement of the cardiovascular, ocular and skeletal systems. This autosomal heritable disease is mainly attributable to a defect in the FBN1 gene. Until 2010, the clinical
Autor:
Jan M. Binnekade, Aline Bouwes, Laure B.M. Robillard, Janneke Horn, Alexander W. den Hartog, Luuk Wieske, Marcus J. Schultz, Anne-Cornélie J. M. de Pont
Publikováno v:
Resuscitation, 83(8), 996-1000. Elsevier Ireland Ltd
Introduction: Treatment with hypothermia has been shown to improve outcome after cardiac arrest (CA). Current consensus is to rewarm at 0.25-0.5 degrees C/h and avoid fever. The aim of this study was to investigate whether active rewarming, the rate
Autor:
Romy Franken, Maarten P. van den Berg, Maarten Groenink, Arthur J. Scholte, Vivian de Waard, Alessandra Maugeri, Alexander W. den Hartog, Gerard Pals, Dimitra Micha, Barbara J.M. Mulder, Aeilko H. Zwinderman, Janneke Timmermans, Fleur S van Dijk, Hanne Meijers-Heijboer, Teodora Radonic
Publikováno v:
Circulation. Cardiovascular genetics, 8(2), 383-388. Lippincott Williams and Wilkins
Circulation: Cardiovascular Genetics, 8(2), 383-388
Circulation. Cardiovascular Genetics, 8, 2, pp. 383-8
Circulation-Cardiovascular Genetics, 8(2), 383-388. LIPPINCOTT WILLIAMS & WILKINS
Circulation. Cardiovascular Genetics, 8, 383-8
Circulation-cardiovascular genetics, 8(2), 383-388. Lippincott Williams and Wilkins
Franken, R, den Hartog, A W, Radonic, T, Micha, D, Maugeri, A, van Dijk, F S, Meijers-Heijboer, H E, Timmermans, J, Scholte, A J, van den Berg, M P, Groenink, M, Mulder, B J M, Zwinderman, A H, de Waard, V & Pals, G 2015, ' Beneficial Outcome of Losartan Therapy Depends on Type of FBN1 Mutation in Marfan Syndrome ', Circulation-cardiovascular genetics, vol. 8, no. 2, pp. 383-388 . https://doi.org/10.1161/CIRCGENETICS.114.000950
Circulation: Cardiovascular Genetics, 8(2), 383-388
Circulation. Cardiovascular Genetics, 8, 2, pp. 383-8
Circulation-Cardiovascular Genetics, 8(2), 383-388. LIPPINCOTT WILLIAMS & WILKINS
Circulation. Cardiovascular Genetics, 8, 383-8
Circulation-cardiovascular genetics, 8(2), 383-388. Lippincott Williams and Wilkins
Franken, R, den Hartog, A W, Radonic, T, Micha, D, Maugeri, A, van Dijk, F S, Meijers-Heijboer, H E, Timmermans, J, Scholte, A J, van den Berg, M P, Groenink, M, Mulder, B J M, Zwinderman, A H, de Waard, V & Pals, G 2015, ' Beneficial Outcome of Losartan Therapy Depends on Type of FBN1 Mutation in Marfan Syndrome ', Circulation-cardiovascular genetics, vol. 8, no. 2, pp. 383-388 . https://doi.org/10.1161/CIRCGENETICS.114.000950
Background— It has been shown that losartan reduces aortic dilatation in patients with Marfan syndrome. However, treatment response is highly variable. This study investigates losartan effectiveness in genetically classified subgroups. Methods and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15f46780b1933f04c984dcc4b24d2930
https://hdl.handle.net/1887/99600
https://hdl.handle.net/1887/99600
Autor:
Romy Franken, Barbara J.M. Mulder, Gerard Pals, Maarten P. van den Berg, Arthur J.H.A. Scholte, Janneke Timmermans, Maarten Groenink, Vivian de Waard, Alexander W. den Hartog, Aeilko H. Zwinderman
Publikováno v:
Journal of the American College of Cardiology, 65(3), 246-254
Journal of the American College of Cardiology, 65(3), 246-254. Elsevier USA
Journal of the American College of Cardiology, 65, 246-54
Journal of the American College of Cardiology, 65, 3, pp. 246-54
Journal of the American College of Cardiology, 65(3), 246-254. ELSEVIER SCIENCE INC
den Hartog, A W, Franken, R, Zwinderman, A H, Timmermans, J, Scholte, A J, van den Berg, M P, de Waard, V, Pals, G, Mulder, B J M & Groenink, M 2015, ' The Risk for Type B Aortic Dissection in Marfan Syndrome ', Journal of the American College of Cardiology, vol. 65, no. 3, pp. 246-254 . https://doi.org/10.1016/j.jacc.2014.10.050
Journal of the American College of Cardiology, 65(3), 246-254. Elsevier USA
Journal of the American College of Cardiology, 65, 246-54
Journal of the American College of Cardiology, 65, 3, pp. 246-54
Journal of the American College of Cardiology, 65(3), 246-254. ELSEVIER SCIENCE INC
den Hartog, A W, Franken, R, Zwinderman, A H, Timmermans, J, Scholte, A J, van den Berg, M P, de Waard, V, Pals, G, Mulder, B J M & Groenink, M 2015, ' The Risk for Type B Aortic Dissection in Marfan Syndrome ', Journal of the American College of Cardiology, vol. 65, no. 3, pp. 246-254 . https://doi.org/10.1016/j.jacc.2014.10.050
Item does not contain fulltext BACKGROUND: Aortic dissections involving the descending aorta are a major clinical problem in patients with Marfan syndrome. OBJECTIVES: The purpose of this study was to identify clinical parameters associated with type
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c1bdb189c5525dbd04cf97b8c49431f
http://hdl.handle.net/1887/99610
http://hdl.handle.net/1887/99610
Autor:
Aeilko H. Zwinderman, Romy Franken, Barbara J.M. Mulder, Vivian de Waard, Stijntje Hibender, Teodora Radonic, Alexander W. den Hartog, Maarten Groenink, Carlie J.M. de Vries
Publikováno v:
PLoS ONE, Vol 9, Iss 9, p e107221 (2014)
PLoS ONE, 9(9), e107221-(7 p.). Public Library of Science
Franken, R, Hibender, S, den Hartog, A W, Radonic, T, de Vries, C J M, Zwinderman, A H, Groenink, M, Mulder, B J M & de Waard, V 2014, ' No Beneficial Effect of General and Specific Anti-Inflammatory Therapies on Aortic Dilatation in Marfan Mice ', PLoS ONE, vol. 9, no. 9, e107221 . https://doi.org/10.1371/journal.pone.0107221
PLoS ONE, 9(9):e107221. Public Library of Science
PLoS ONE
PLoS ONE, 9(9), e107221-(7 p.). Public Library of Science
Franken, R, Hibender, S, den Hartog, A W, Radonic, T, de Vries, C J M, Zwinderman, A H, Groenink, M, Mulder, B J M & de Waard, V 2014, ' No Beneficial Effect of General and Specific Anti-Inflammatory Therapies on Aortic Dilatation in Marfan Mice ', PLoS ONE, vol. 9, no. 9, e107221 . https://doi.org/10.1371/journal.pone.0107221
PLoS ONE, 9(9):e107221. Public Library of Science
PLoS ONE
Aims Patients with Marfan syndrome have an increased risk of life-threatening aortic complications, mostly preceded by aortic dilatation. In the FBN1(C1039G/+) Marfan mouse model, losartan decreases aortic root dilatation. We recently confirmed this
Autor:
Aeilko H. Zwinderman, Henk A. Marquering, Vivian de Waard, Janneke Timmermans, Alexander W. den Hartog, Romy Franken, Teodora Radonic, Arthur J. Scholte, Maarten P. van den Berg, Maarten Groenink, Barbara J.M. Mulder, Anje M. Spijkerboer
Publikováno v:
European Heart Journal, 34(45), 3491-3500
European Heart Journal, 34(45), 3491-3500. Oxford University Press
European Heart Journal, 34, 3491-500
Groenink, M, den Hartog, A W, Franken, R, Radonic, T, de Waard, V, Timmermans, J, Scholte, A J, van den Berg, M P, Spijkerboer, A M, Marquering, H A, Zwinderman, A H & Mulder, B J M 2013, ' Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial ', European Heart Journal, vol. 34, no. 45, pp. 3491-3500 . https://doi.org/10.1093/eurheartj/eht334
European Heart Journal, 34, 45, pp. 3491-500
European heart journal, 34(45), 3491-3500. Oxford University Press
European Heart Journal, 34(45), 3491-3500. Oxford University Press
European Heart Journal, 34, 3491-500
Groenink, M, den Hartog, A W, Franken, R, Radonic, T, de Waard, V, Timmermans, J, Scholte, A J, van den Berg, M P, Spijkerboer, A M, Marquering, H A, Zwinderman, A H & Mulder, B J M 2013, ' Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial ', European Heart Journal, vol. 34, no. 45, pp. 3491-3500 . https://doi.org/10.1093/eurheartj/eht334
European Heart Journal, 34, 45, pp. 3491-500
European heart journal, 34(45), 3491-3500. Oxford University Press
Item does not contain fulltext AIM: Patients with Marfan syndrome have an increased risk of life-threatening aortic complications, mostly preceded by aortic dilatation. Treatment with losartan, an angiotensin-II receptor-1 blocker, may reduce aortic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::447a93e8828fd7f648a05dfb778ef274
http://hdl.handle.net/1887/101411
http://hdl.handle.net/1887/101411